Company Profile
Welcome to our world. A world where all South Africans have
access to world class medicines at affordable prices. A world where
affordable healthcare is a right, not a privilege. A world where
the final measure of our success is a simple curve - the smile of
health regained.
At Cipla Medpro we subscribe to the ethos that all South
Africans should have access to world class, yet affordable
medicines and to that end we endeavour to produce medicines of
superior quality and to introduce these medicines to our society as
inexpensively as possible, thereby lessening the burden of high
drug costs and bettering the health and lives of all South
Africans.
Cipla Medpro (Pty) Ltd, is South Africa's fastest growing
pharmaceutical company and a leading provider of chronic medicines
to the public and private sectors.* It commands an ever-increasing
share within, inter alia, the cardiovascular, antiretroviral,
respiratory and neuro-psychiatric categories. Headquartered in Cape
Town, with regional offices throughout the country, Cipla is listed
on the Johannesburg Securities Exchange (JSE) through holding
company Cipla Medpro South Africa Limited.
In 1993, CEO Jerome Smith founded the business Medpro
Pharmaceutica, one of South Africa's first generic medicine
companies. After strategically aligning the fast growing business
with Cipla, India's largest pharmaceutical company, Smith proceeded
to lead Cipla Medpro to its current standing as a top 3 South
African pharmaceutical company by volume and top 3 pharmaceutical
company by value.* He achieved this through trusted, passionate
staff and the invaluable mentorship of Mr Amar Lulla, Dr Yusuf
Hamied and Mr Muku Hamied, Senior Officers at Cipla India.
The company's strong relationship with Cipla has been key to
allowing the company to continuously increase its market share
through the launch of a number of new molecules and establishing a
solid reputation for swift launches and championing affordable
healthcare.
In December 2005, in one of the largest transactions to date in
the local pharmaceutical industry, the shareholders of Cipla Medpro
sold the business to Johannesburg Securities Exchange-listed
pharmaceutical group Enaleni Pharmaceuticals Ltd.
In August 2007, following a revision of the group's focus and
strategy, the Enaleni Board of Directors appointed Jerome Smith as
CEO of the Enaleni Pharmaceuticals Group. In October that same year
Cipla Medpro Financial Director Chris Aucamp was appointed Group
CFO.
In July 2008 shareholders approved the change of the group's
name, Enaleni Pharmaceuticals Ltd to Cipla Medpro South Africa Ltd.
The new name, which came into effect in November 2008, better
reflects the group's positioning in the local pharmaceutical market
through its wholly owned subsidiary, Cipla Medpro Holdings (Pty)
Ltd. Mr Smith and Mr Aucamp continue to serve on the Board of
Directors as CEO and CFO respectively.
*Source: IMS June 2010